Effects of vildagliptin (Galvus®) therapy in patients with type 2 diabetes mellitus after heart transplantation

References

• Higgins J Pflugfelder PW Kostuk WJ Increased morbidity in diabetic cardiac transplant recipients Can J Cardiol 2009 25 4 e125 e129 19340357
   PubMed Web of Science ®Google Scholar
• Hjelmesaeth J Hartmann A Leivestad T The impact of early-diagnosed new-onset post-transplantation diabetes mellitus on survival and major cardiac events Kidney Int 2006 69 3 588 595 16395250
   PubMed Web of Science ®Google Scholar
• Munoz E Lonquist JL Radovancevic B Long-term results in diabetic patients undergoing heart transplantation J Heart Lung Transplant 1992 11 5 943 949 1420243
   PubMed Web of Science ®Google Scholar
• Inzucchi SE Oral antihyperglycemic therapy for type 2 diabetes: scientific review JAMA 2002 287 3 360 372 11790216
   PubMed Web of Science ®Google Scholar
• Nesto RW Bell D Bonow RO Thiazolidinedione use, fluid retention, and congestive heart failure: a consensus statement from the American Heart Association and American Diabetes Association Diabetes Care 2004 27 1 256 263 14693998
   PubMed Web of Science ®Google Scholar
• Holst JJ Orskov C The incretin approach for diabetes treatment: modulation of islet hormone release by GLP-1 agonism Diabetes 2004 53 Suppl 3 S197 S204 15561911
   PubMed Web of Science ®Google Scholar
• Holst JJ Deacon CF Glucagon-like peptide 1 and inhibitors of dipeptidyl peptidase IV in the treatment of type 2 diabetes mellitus Curr Opin Pharmacol 2004 4 6 589 596 15525549
   PubMed Web of Science ®Google Scholar
• Azuma K Radikova Z Mancino J Measurements of islet function and glucose metabolism with the dipeptidyl peptidase 4 inhibitor vildagliptin in patients with type 2 diabetes J Clin Endocrinol Metab 2008 93 2 459 464 18042650
   PubMed Web of Science ®Google Scholar
• Ahrén B Landin-Olsson M Jansson PA Svensson M Holmes D Schweizer A Inhibition of dipeptidyl peptidase-4 reduces glycemia, sustains insulin levels, and reduces glucagon levels in type 2 diabetes J Clin Endocrinol Metab 2004 89 5 2078 2084 15126524
   PubMed Web of Science ®Google Scholar
• D’Alessio DA Denney AM Hermiller LM Treatment with the dipeptidyl peptidase-4 inhibitor vildagliptin improves fasting islet-cell function in subjects with type 2 diabetes J Clin Endocrinol Metab 2009 94 1 81 88 18957505
   PubMed Web of Science ®Google Scholar
• Mathieu C The scientific evidence: vildagliptin and the benefits of islet enhancement Diabetes Obes Metab 2009 11 Suppl 2 9 17 19385979
   PubMed Web of Science ®Google Scholar
• Mari A Sallas WM He YL Vildagliptin, a dipeptidyl peptidase-IV inhibitor, improves model-assessed beta-cell function in patients with type 2 diabetes J Clin Endocrinol Metab 2005 90 8 4888 4894 15886245
   PubMed Web of Science ®Google Scholar
• Mari A Scherbaum WA Nilsson PM Characterization of the influence of vildagliptin on model-assessed-cell function in patients with type 2 diabetes and mild hyperglycemia J Clin Endocrinol Metab 2008 93 1 103 109 17925336
   PubMed Web of Science ®Google Scholar
• Pi-Sunyer FX Schweizer A Mills D Dejager S Efficacy and tolerability of vildagliptin monotherapy in drug-naïve patients with type 2 diabetes Diabetes Res Clin Pract 2007 76 1 132 138 17223217
   PubMed Web of Science ®Google Scholar
• Ahrén B Vildagliptin: an inhibitor of dipeptidyl peptidase-4 with antidiabetic properties Expert Opin Investig Drugs 2006 15 4 431 442
   PubMed Web of Science ®Google Scholar
• Pratley RE Jauffret-Kamel S Galbreath E Holmes D Twelve-week monotherapy with the DPP-4 inhibitor vildagliptin improves glycemic control in subjects with type 2 diabetes Horm Metab Res 2006 38 6 423 428 16823726
   PubMed Web of Science ®Google Scholar
• Ristic S Byiers S Foley J Holmes D Improved glycaemic control with dipeptidyl peptidase-4 inhibition in patients with type 2 diabetes: vildagliptin (LAF237) dose response Diabetes Obes Metab 2005 7 6 692 698 16219012
   PubMed Web of Science ®Google Scholar
• Bosi E Camisasca RP Collober C Rochotte E Garber AJ Effects of vildagliptin on glucose control over 24 weeks in patients with type 2 diabetes inadequately controlled with metformin Diabetes Care 2007 30 4 890 895 17277036
   PubMed Web of Science ®Google Scholar
• Bosi E Dotta F Jia Y Goodman M Vildagliptin plus metformin combination therapy provides superior glycaemic control to individual monotherapy in treatment-naive patients with type 2 diabetes mellitus Diabetes Obes Metab 2009 11 5 506 515 19320662
   PubMed Web of Science ®Google Scholar
• Rosenstock J Fitchet M Vildagliptin: clinical trials programme in monotherapy and combination therapy for type 2 diabetes Int J Clin Pract Suppl 2008 159 15 23 18269437
   PubMedGoogle Scholar
• Garber AJ Foley JE Banerji MA Effects of vildagliptin on glucose control in patients with type 2 diabetes inadequately controlled with a sulphonylurea Diabetes Obes Metab 2008 10 11 1047 1056 18284434
   PubMed Web of Science ®Google Scholar
• Rosenstock J Kim SW Baron MA Efficacy and tolerability of initial combination therapy with vildagliptin and pioglitazone compared with component monotherapy in patients with type 2 diabetes Diabetes Obes Metab 2007 9 2 175 185 17300593
   PubMed Web of Science ®Google Scholar
• Garber AJ Schweizer A Baron MA Rochotte E Dejager S Vildagliptin in combination with pioglitazone improves glycaemic control in patients with type 2 diabetes failing thiazolidinedione monotherapy: a randomized, placebo-controlled study Diabetes Obes Metab 2007 9 2 166 174 17300592
   PubMed Web of Science ®Google Scholar
• Fonseca V Schweizer A Albrecht D Baron MA Chang I Dejager S Addition of vildagliptin to insulin improves glycaemic control in type 2 diabetes Diabetologia 2007 50 6 1148 1155 17387446
   PubMed Web of Science ®Google Scholar
• Fonseca V Baron M Shao Q Dejager S Sustained efficacy and reduced hypoglycemia during one year of treatment with vildagliptin added to insulin in patients with type 2 diabetes mellitus Horm Metab Res 2008 40 6 427 430 18401832
   PubMed Web of Science ®Google Scholar
• Matikainen N Mänttäri S Schweizer A Vildagliptin therapy reduces postprandial intestinal triglyceride-rich lipoprotein particles in patients with type 2 diabetes Diabetologia 2006 49 9 2049 2057 16816950
   PubMed Web of Science ®Google Scholar
• Mathieu C Degrande E Vildagliptin: a new oral treatment for type 2 diabetes mellitus Vasc Health Risk Manag 2008 4 6 1349 1360 19337548
   PubMedGoogle Scholar
• Foley JE Jordan J Weight neutrality with the DPP-4 inhibitor, vildagliptin: mechanistic basis and clinical experience Vasc Health Risk Manag 2010 6 541 548 20730070
   PubMedGoogle Scholar
• Ayalasomayajula SP Dole K He YL Evaluation of the potential for steady-state pharmacokinetic interaction between vildagliptin and simvastatin in healthy subjects Curr Med Res Opin 2007 23 12 2913 2920 17931461
   PubMed Web of Science ®Google Scholar
• Pinelli NR Nemerovski CW Koelling TM Successful long-term use of sitagliptin for the treatment of new-onset diabetes mellitus after solid organ transplantation: a case report Transplant Proc 2011 43 5 2113 2115 21693339
   PubMed Web of Science ®Google Scholar
• Koch A Daniel V Dengler TJ Schnabel PA Hagl S Sack FU Effectivity of a T-cell-adapted induction therapy with anti-thymocyte globulin (Sangstat) J Heart Lung Transplant 2005 24 6 708 713 15949731
   PubMed Web of Science ®Google Scholar
• Ahrén B Gomis R Standl E Mills D Schweizer A Twelve- and 52-week efficacy of the dipeptidyl peptidase IV inhibitor LAF237 in metformin-treated patients with type 2 diabetes Diabetes Care 2004 27 12 2874 2880 15562200
   PubMed Web of Science ®Google Scholar
• He YL Ligueros-Saylan M Sunkara G Vildagliptin, a novel dipeptidyl peptidase IV inhibitor, has no pharmacokinetic interactions with the antihypertensive agents amlodipine, valsartan, and ramipril in healthy subjects J Clin Pharmacol 2008 48 1 85 95 17986525
   PubMed Web of Science ®Google Scholar